- Home
- WPP vs ADMA Comparison
WPP vs ADMA Comparison
Compare WPP & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- ADMA
- Stock Information
- Founded
- WPP 1985
- ADMA 2004
- Country
- WPP United Kingdom
- ADMA United States
- Employees
- WPP N/A
- ADMA N/A
- Industry
- WPP Advertising
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WPP Consumer Discretionary
- ADMA Health Care
- Exchange
- WPP Nasdaq
- ADMA Nasdaq
- Market Cap
- WPP 5.9B
- ADMA 5.1B
- IPO Year
- WPP N/A
- ADMA N/A
- Fundamental
- Price
- WPP $26.80
- ADMA $15.55
- Analyst Decision
- WPP Sell
- ADMA Strong Buy
- Analyst Count
- WPP 1
- ADMA 3
- Target Price
- WPP N/A
- ADMA $27.67
- AVG Volume (30 Days)
- WPP 360.8K
- ADMA 3.0M
- Earning Date
- WPP 08-07-2025
- ADMA 11-06-2025
- Dividend Yield
- WPP 9.61%
- ADMA N/A
- EPS Growth
- WPP 86.47
- ADMA 469.09
- EPS
- WPP 0.47
- ADMA 0.85
- Revenue
- WPP $19,423,208,660.00
- ADMA $474,174,000.00
- Revenue This Year
- WPP N/A
- ADMA $21.08
- Revenue Next Year
- WPP N/A
- ADMA $25.98
- P/E Ratio
- WPP $11.12
- ADMA $19.06
- Revenue Growth
- WPP N/A
- ADMA 43.58
- 52 Week Low
- WPP $24.28
- ADMA $13.50
- 52 Week High
- WPP $57.37
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- WPP 47.29
- ADMA 32.76
- Support Level
- WPP $26.70
- ADMA $15.74
- Resistance Level
- WPP $27.50
- ADMA $17.17
- Average True Range (ATR)
- WPP 0.42
- ADMA 0.51
- MACD
- WPP 0.18
- ADMA -0.11
- Stochastic Oscillator
- WPP 53.95
- ADMA 0.74
About WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.